Let’s be real: even with the best intentions, AI systems can reflect our own unconscious biases. As Daniel Kahneman and Amos Tversky famously demonstrated in their groundbreaking work on Prospect Theory, humans are prone to cognitive biases that influence our…
HOME > BUSINESS
BUSINESS
- Takeda Files NDA for Malignant Lymphoma Treatment Brentuximab Vedotin in Japan
March 26, 2013
- JAK Inhibitor Xeljanz Approved for RA: Pfizer Japan
March 26, 2013
- Regtect Approved for Supporting Maintenance of Abstinence in Patients with Alcohol Dependence: Nippon Shinyaku
March 26, 2013
- Daiichi Sankyo Aims for Approval of Enbrel Biosimilar in FY2016: President Nakayama
March 26, 2013
- Daiichi Sankyo’s Osteoporosis Treatment Pralia Approved
March 26, 2013
- New Settai Rules Halfway to Establishment; Some in Industry Want Further Rules as Well
March 26, 2013
- Astellas Ties Up with Tokyo Tech and Nagasaki University to Research Anti-Dengue Virus Treatment
March 25, 2013
- Daiichi Sankyo Mulls Biz Platform after Olmesartan LOE: New 5 Year Plan
March 25, 2013
- Takeda Returns Global Rights to NPS Pharmaceuticals for Preotact and Revestive
March 25, 2013
- Israeli-Originated High-Techs Highlighted at Israel Life Science Forum 2013
March 25, 2013
- Merck Serono to Develop Anticancer Drugs for Asian Patients at R&D Hub in Tokyo
March 22, 2013
- New Product Launches “On Track,” Sales Brisk: Otsuka Holdings Pres. Higuchi
March 22, 2013
- SSRI Predicts SGLT-2 Inhibitor Market to Grow to around 60 Billion Yen in 5th Year after Launch
March 22, 2013
- Japan Pharmas Accelerating Drives to Set Up Medical Affairs Units
March 21, 2013
- MHLW Lifts All-Case Surveillance for Treakisym: SymBio, Eisai
March 19, 2013
- Alcon Japan, Kyowa Kirin Adjust Shipments of Anti-Allergy Drugs
March 19, 2013
- Daiichi Sankyo to File Prasugrel for Cardiovascular Disease in PCI Patients in Japan
March 19, 2013
- Pfizer Japan Launches OAB Treatment Toviaz
March 19, 2013
- Generic Companies Increasing Focus on Fast-growing Oncology Market; Shift to Overseas Production Will Spur Cost Competition
March 18, 2013
- Eisai Appoints Its First Female Executive
March 18, 2013
ページ
As Japan approaches the Fiscal System Council’s “autumn recommendation,” a notable shift is taking shape. The Ministry of Finance (MOF),…
Japan is considering a new approach to its “special” market expansion re-pricing that would exclude drug sales tied to private…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…